Q3176651 (Q3176651): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): The ability to predict the response of hepatocarcinoma (HCC) to treatment by transarterial chemoembolisation (TACE) with microspheres loaded with adriamcin pending liver orthotopic transplantation (TOH) is limited. The effectiveness of this response has a strong prognostic character. The presence of circulating tumor cells in peripheral blood (CTCs) and findings of PET-TAC and dynamic NMR with gadoxetic acid may play a useful role in their evalu...) |
||||||||||||||
| Property / summary | |||||||||||||||
The ability to predict the response of hepatocarcinoma (HCC) to treatment by transarterial chemoembolisation (TACE) with microspheres loaded with adriamcin pending liver orthotopic transplantation (TOH) is limited. The effectiveness of this response has a strong prognostic character. The presence of circulating tumor cells in peripheral blood (CTCs) and findings of PET-TAC and dynamic NMR with gadoxetic acid may play a useful role in their evaluation. The objective of the study will focus on the determination of the profile of peripheral blood CTCs as well as the modifications detected in PET-TAC and MRI with pre and post-TACE gadoxetic acid in the anatomopathological results (necrosis and tumor proliferation) of the explanted liver in patients with HCC. Likewise, these findings will be correlated with HCC’s tumor response to TACE and disease-free survival after TOH. For this we have designed a non-randomised prospective cohort study, to be developed between January 2014-December 2016. The study will be carried out in the Hepatic Transplantation Unit of the Hospital Clínica Universitario Virgen de la Arrixaca, including 30 patients, with an age range between 18 and 70 years and with the diagnosis of HCC with Milan criteria in which TACE is performed as a bridging therapy to transplant. Patients with any other therapeutic technique for the treatment of HCC prior to TOH other than TACE will be excluded. (English) | |||||||||||||||
| Property / summary: The ability to predict the response of hepatocarcinoma (HCC) to treatment by transarterial chemoembolisation (TACE) with microspheres loaded with adriamcin pending liver orthotopic transplantation (TOH) is limited. The effectiveness of this response has a strong prognostic character. The presence of circulating tumor cells in peripheral blood (CTCs) and findings of PET-TAC and dynamic NMR with gadoxetic acid may play a useful role in their evaluation. The objective of the study will focus on the determination of the profile of peripheral blood CTCs as well as the modifications detected in PET-TAC and MRI with pre and post-TACE gadoxetic acid in the anatomopathological results (necrosis and tumor proliferation) of the explanted liver in patients with HCC. Likewise, these findings will be correlated with HCC’s tumor response to TACE and disease-free survival after TOH. For this we have designed a non-randomised prospective cohort study, to be developed between January 2014-December 2016. The study will be carried out in the Hepatic Transplantation Unit of the Hospital Clínica Universitario Virgen de la Arrixaca, including 30 patients, with an age range between 18 and 70 years and with the diagnosis of HCC with Milan criteria in which TACE is performed as a bridging therapy to transplant. Patients with any other therapeutic technique for the treatment of HCC prior to TOH other than TACE will be excluded. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The ability to predict the response of hepatocarcinoma (HCC) to treatment by transarterial chemoembolisation (TACE) with microspheres loaded with adriamcin pending liver orthotopic transplantation (TOH) is limited. The effectiveness of this response has a strong prognostic character. The presence of circulating tumor cells in peripheral blood (CTCs) and findings of PET-TAC and dynamic NMR with gadoxetic acid may play a useful role in their evaluation. The objective of the study will focus on the determination of the profile of peripheral blood CTCs as well as the modifications detected in PET-TAC and MRI with pre and post-TACE gadoxetic acid in the anatomopathological results (necrosis and tumor proliferation) of the explanted liver in patients with HCC. Likewise, these findings will be correlated with HCC’s tumor response to TACE and disease-free survival after TOH. For this we have designed a non-randomised prospective cohort study, to be developed between January 2014-December 2016. The study will be carried out in the Hepatic Transplantation Unit of the Hospital Clínica Universitario Virgen de la Arrixaca, including 30 patients, with an age range between 18 and 70 years and with the diagnosis of HCC with Milan criteria in which TACE is performed as a bridging therapy to transplant. Patients with any other therapeutic technique for the treatment of HCC prior to TOH other than TACE will be excluded. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 18:35, 12 October 2021
Project Q3176651 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3176651 in Spain |
Statements
30,400.0 Euro
0 references
38,000.0 Euro
0 references
80.0 percent
0 references
1 January 2014
0 references
31 March 2017
0 references
FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA (FFIS)
0 references
37°59'32.57"N, 1°7'49.94"W
0 references
30030
0 references
La capacidad de predecir la respuesta del hepatocarcinoma (HCC) al tratamiento mediante quimioembolización transarterial (TACE) con microesferas cargadas con adriamicina en espera de un trasplante ortotópico hepático (TOH) es limitada. La eficacia de esta respuesta tiene un marcado carácter pronóstico. La presencia de células tumorales circulantes en sangre periférica (CTCs) y los hallazgos del PET-TAC y la RNM dinámica con ácido gadoxético pueden jugar un papel útil en su evaluación. El objetivo del trabajo se centrará en la determinación del perfil de CTCs en sangre periférica así como las modificaciones detectadas en el PET-TAC y la RNM con ácido gadoxético pre y post-TACE en los resultados anatomopatológicos (necrosis y proliferación tumoral) del hígado explantado en pacientes con HCC. Así mismo se correlacionarán estos hallazgos con la respuesta tumoral del HCC a la TACE y con la supervivencia libre de enfermedad tras el TOH. Para ello hemos diseñado un estudio de cohortes prospectivo no randomizado, a desarrollar entre Enero de 2014-Diciembre de 2016. El estudio se realizará en la Unidad de Trasplante Hepático del Hospital Clínico Universitario Virgen de la Arrixaca, incluyéndose a 30 pacientes, con un intervalo de edad entre 18-70 años y con el diagnóstico de HCC con criterios de Milán en los que se realice una TACE como terapia puente al trasplante. Los pacientes en los que se haya realizado cualquier otra técnica terapéutica para el tratamiento del HCC previa al TOH distinta de la TACE serán excluidos. (Spanish)
0 references
The ability to predict the response of hepatocarcinoma (HCC) to treatment by transarterial chemoembolisation (TACE) with microspheres loaded with adriamcin pending liver orthotopic transplantation (TOH) is limited. The effectiveness of this response has a strong prognostic character. The presence of circulating tumor cells in peripheral blood (CTCs) and findings of PET-TAC and dynamic NMR with gadoxetic acid may play a useful role in their evaluation. The objective of the study will focus on the determination of the profile of peripheral blood CTCs as well as the modifications detected in PET-TAC and MRI with pre and post-TACE gadoxetic acid in the anatomopathological results (necrosis and tumor proliferation) of the explanted liver in patients with HCC. Likewise, these findings will be correlated with HCC’s tumor response to TACE and disease-free survival after TOH. For this we have designed a non-randomised prospective cohort study, to be developed between January 2014-December 2016. The study will be carried out in the Hepatic Transplantation Unit of the Hospital Clínica Universitario Virgen de la Arrixaca, including 30 patients, with an age range between 18 and 70 years and with the diagnosis of HCC with Milan criteria in which TACE is performed as a bridging therapy to transplant. Patients with any other therapeutic technique for the treatment of HCC prior to TOH other than TACE will be excluded. (English)
12 October 2021
0 references
Murcia
0 references
Identifiers
PI13_01195
0 references